US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib from btz Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: Dr Sudhir Manda speaks to ecancer about the study he presented during the EHA 2020 virtual meeting. nnHe presents the US MM-6 study, a community-based study looking at long-term proteasome inhibition in multiple myeloma (MM) following an in-class transition from bortezomib (btz) to ixazomib (ixa).nnDr Manda gives a detailed account of the trial design, results and the ongoing enrolment status of this clinical trial. He finalises by explaining what clinical and patient impact this research will h